Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1245
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1141–1152 of 1,245 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027
Site status not listed — check the official record
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Recruiting Not applicable Interventional

STIMIT Activator 1 IDE Study

NCT05883163
Status at this site: Recruiting
View directory record Official record
Conditions
Diaphragm Issues
Interventions
Stimit Activator 1
Device
Lead sponsor
Stimit AG
Industry
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting Phase 2 Interventional

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617
Site status not listed — check the official record
View directory record Official record
Conditions
Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation
Radiation · Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
14
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting Not applicable Interventional

(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

NCT05364502
Site status not listed — check the official record
View directory record Official record
Conditions
Arterial Bleeding in Solid Organs and Peripheral Arteries
Interventions
Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter
Device
Lead sponsor
Instylla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Long Beach, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

NCT03803423
Status at this site: Enrolling by invitation
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
The Donor App
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
6
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting Not applicable Interventional

Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection

NCT03033043
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Dissection Type B
Interventions
Relay Pro Stent-Graft
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Recruiting Phase 3 Interventional

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

NCT05929768
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
955
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AMP SCZ® Observational Study: PREDICT-DPACC

NCT05905003
Site status not listed — check the official record
View directory record Official record
Conditions
Clinical High Risk, Psychosis, Remission, Conversion
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 30 Years
Enrollment
2,617 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting No phase listed Observational

OCS Heart Perfusion Post-Approval Registry

NCT05047068
Site status not listed — check the official record
View directory record Official record
Conditions
Transplant
Interventions
OCS Heart System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Recruiting No phase listed Observational

US National OCS Heart Perfusion (OHP) Registry

NCT05915299
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Transplant
Interventions
OCS Heart
Device
Lead sponsor
TransMedics
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
37
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 3, 2026, 11:08 AM EST
Active, not recruiting Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions
ABBV-400, Trifluridine/Tipiracil, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 3, 2026, 11:08 AM EST

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.